| IFCT-1805 ELDERLY |
Patients âgés |
Chimiothérapie +/- atezolizumab |
50 |
262 |
500 |
| IFCT-1802 SAVIMMUNE |
PS2/3 |
Durvalumab |
7 |
12 |
67 |
| IFCT-1902 ORAKLE |
ALK positif |
Lorlatinib |
14 |
16 |
112 |
| IFCT-1804 ORBITAL |
EGFR positif + méta cérébrales ou leptoméningées |
Osimertinib |
19 |
33 |
113 |
| IFCT-1904 ENCO-BRAF |
BRAF V600E |
Encorafenib + binimetinib |
10 |
17 |
144 |
| IFCT-2002 14-GENE |
Stades I ou IIA |
14-Gene Prognostic Assay + chemotherapy or observation |
4 |
6 |
100 |
| IFCT-2003 ALBATROS |
ROS1 positif |
Lorlatinib |
8 |
10 |
84 |
| IFCT-2004 BLaDE |
BRAF V600 |
Dabrafenib-trametinib |
25 |
79 |
200 |
| IFCT-1905 CLINATEZO |
CPC |
Cohorte ATU |
37 |
286 |
500 |
